Postdoc: Synuclein Biology & Neurodegeneration

BioSpace; Boston (MA); On-site; USD 58,000 - 123,000; Full time

Job summary

Lilly’s Neurodegeneration Biology group in Boston seeks a Postdoctoral Scientist to investigate α-synuclein dysfunction and aggregation, using iPSC-derived neuronal models and engineered cell lines to build a mechanistic basis for new therapies in synucleinopathy.

This fixed-term role focuses on quantitative aggregation biochemistry, cell biology, and translational neuroscience within a collaborative drug discovery environment.

Qualifications

• PhD in cell biology, biochemistry, molecular biology, neuroscience, protein biophysics, or a related field.
• Hands-on expertise in protein aggregation biochemistry, including ThT-based kinetic assays.
• Experience generating and engineering mammalian cell lines, including CRISPR editing, lentiviral transduction, or stable line development.
• Qualified applicants must be authorized to work in the United States on a full-time basis.

Responsibilities

• Define molecular and cellular mechanisms that drive α-synuclein aggregation and dysfunction.
• Develop cellular models including engineered cell lines and iPSC-derived neurons.
• Establish aggregation paradigms and quantify kinetics and misfolding outcomes.
• Apply Thioflavin T (ThT) assays and biophysical readouts to assess aggregation.
• Validate findings in neuronal disease models and collaborate with Lilly Boston and external partners.
• Present results at meetings and contribute to publications; maintain electronic lab notebooks.

Skills

Protein aggregation biochemistry

Cell engineering

Mammalian cell lines

Biochemical/biophysical character

Scientific communication

Education

PhD in life sciences

Tools

Confocal microscopy

iPSC-derived neurons

Job description

Lilly’s Neurodegeneration Biology group in Boston seeks a Postdoctoral Scientist to investigate α-synuclein dysfunction and aggregation, using iPSC-derived neuronal models and engineered cell lines to build a mechanistic basis for new therapies in synucleinopathy.

This fixed-term role focuses on quantitative aggregation biochemistry, cell biology, and translational neuroscience within a collaborative drug discovery environment.